KODK News & Events

Kodiak announced topline results in the GLOW2 Phase 3 superiority study of Zenkuda for the treatment of patients with diabetic retinopathy. In GLOW2, patients were randomized to receive either sham injection or Zenkuda via intravitreal injection at progressively extended intervals after a loading phase, with all patients on 6-month dosing by the end of the study. A total of 62.5% of patients treated with Zenkuda achieved a greater than or equal to 2-step improvement in DRSS score at Week 48, compared with 3.3% in the sham group, meeting the primary endpoint of superiority to sham with high statistical significance. Zenkuda also demonstrated superiority in the two alpha-controlled secondary endpoints, with high statistical significance: Zenkuda demonstrated superiority in the key secondary endpoint of reducing the risk of developing prespecified sight-threatening complications, including new or worsening proliferative DR or center-involving DME, by 85% compared to sham through Week 48. These results support the GLOW1 study results, in which Zenkuda reduced this risk by 89%. Overall,13.7% of patients on Zenkuda achieved a greater than or equal to3-step improvement in DRSS versus 0% with sham, an improvement comparable to GLOW1, in which 5.6% of patients on Zenkuda achieved a greater than or equal to3-step improvement in DRSS versus 0% with sham. Zenkuda was well-tolerated with low rates of common ocular adverse events. Notably, no cases of intraocular inflammation were reported in the study, and no cases of retinal vasculitis or occlusive retinal vasculitis were observed. The incidence of cataract in the study eye was low and in line with expected background rates in patients with DR. Consistent with a real-world diabetic patient population, GLOW2 included patients using GLP-1 medications. These patients were well-balanced between treatment arms. Among patients using GLP-1 medications, Zenkuda achieved a greater than or equal to 2-step improvement in DRSS from baseline to Week 48 in 60% of patients compared with 64.3% in patients not using GLP-1 medications.

Stock futures are modestly higher ahead of the open as investors continue to navigate the fallout from the energy shock tied to the conflict involving Iran and the ongoing disruption to oil flows through the Strait of Hormuz. Sentiment remains fragile after a volatile week in which markets repeatedly swung in response to headlines from the Middle East and sharp moves in crude oil.Oil remains the central macro driver and analysts have revised their price expectations higher as disruptions to tanker traffic and energy infrastructure continue to threaten global supply. The International Energy Agency has already announced plans for a large coordinated release of emergency reserves in an attempt to stabilize markets, but traders remain focused on whether supply disruptions will persist. At the same time, the U.S. government has temporarily allowed the sale of previously restricted Russian oil shipments to increase supply and relieve pressure on global markets, highlighting the degree to which energy policy has become intertwined with geopolitical developments.Fund flows this week show investors pulling billions of dollars out of global equity funds while moving capital into cash and short-term bond funds, signaling a shift toward defensive positioning as the geopolitical situation evolves. Volatility has also risen, with the CBOE Volatility Index climbing into the high-20s, underscoring the nervous tone across financial markets.In pre-market trading, S&P 500 futures rose 0.54%, Nasdaq futures rose 0.52% and Dow futures rose 0.55%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Klarnaup 7% after disclosing Michael Moritz, chairman, purchased 3,472,845 ordinary shares between March 3 and March 11 and David Fock, chief product and design officer, purchased 27,000 ordinary shares on March 9ImmunityBioup 4% after completing manufacturing engineering programs, NK2022 and NK2023, establishing a leukapheresis-to-manufacturing pathway for its autologous memory cytokine-enhanced natural killer cell therapy platformNioup 3% after HSBC upgraded the stock to Buy with a price target of $6.80UP AFTER EARNINGS -Kodakup 8%Nektarup 2%Rubrikup 2%DOWN AFTER EARNINGS -KinderCare Learningdown 33%EverCommercedown 23%Once Upon a Farmdown 15%Ulta Beautydown 8%ServiceTitandown 6%LOWER -Adobedown 8% after announcing that Shantanu Narayen, who has served as CEO of Adobe for eighteen years, has decided to transition from his position as CEO but will remain as Chair of the Board

Investor sentiment is being seared by images of burning cargo ships blazing across the major media outlets last night and headlines out this afternoon that Iranian boats are placing mines to threaten commercial ships in a bid to choke off a major shipping route in the Strait of Hormuz and inflict economic damage on the West.  Equity markets finished the day near the lows with broad-based losses as Industrials and Consumer Cyclical sectors were hit especially hard.  Energy remains bid thanks to Crude Oil having ripped higher for the second consecutive day to trade above $96, while the Vix  has jumped north of the 27-handle.   Meanwhile, Treasuries are not attracting a flight to safety bid.  The yield on the 10-year Note is now near 4.3% - up almost 30 basis points from the Friday just before missiles were fired on Tehran - as implications of inflationary pressures stoked by higher oil prices muddy the outlook for renewed easing by the FOMC.In the opening hour of the evening session, the mood is less panicked for the time being as S&P 500 and Nasdaq 100 futures hold steady, up about 0.2%.  Precious metals are trading lower for the second consecutive day, tracking the strengthening inverse correlation with US Dollar as the greenback rallied once again.Among key afterhours earnings, Adobeinvestors were not enthused by the company's better than expected Q1 results, and the news of its CEO leaving after 18 years on the job compounded pressure on stock that has already been impacted by the AI-threat panic in the software space.  Shares are down over 7% and tested the downside of $250 level - the lowest since late February - with year-to-date losses for Adobe now approaching 30%.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Eastman Kodakup 11.6%Nektar Therapeuticsup 3.0%Rubrikup 1.5%DOWN AFTER EARNINGS -Ulta Beautydown 8.1%Adobedown 7.4%ServiceTitandown 7.2%SentinelOnedown 4.9%Lennardown 1.3%ALSO LOWER -PAR Technology Corporationdown 22.7% after convertible debt offeringInsulet Corporationdown 7.6%

Reports Q4 revenue $290M vs $266M last year. "Kodak ended 2025 with a strong fourth quarter, which has created a foundation for growth in 2026," said Jim Continenza, Kodak's Executive Chairman and CEO. "We continue to execute the long-term plan we began in 2019, which focuses on de-levering the company while continuing to invest in our infrastructure and new product innovation. Those investments are now paying dividends. Today Kodak has a stronger balance sheet than we've had in years, and we have reduced our annual interest expense by approximately $40 million. Our print business has launched 14 new products in the past few years, and our AM&C unit has introduced a range of still films and developed a number of growth initiatives in promising new businesses. We have updated our internal IT and reporting systems which allow us to streamline processes, reduce operating expenses and better serve our customers. I am optimistic about taking the next step by operating and selling our way to sustainable growth."